Baraldi P G, Balboni G, Pavani M G, Spalluto G, Tabrizi M A, Clercq E D, Balzarini J, Bando T, Sugiyama H, Romagnoli R
Dipartimento di Scienze Farmaceutiche, Università di Ferrara, 44100 Ferrara, Italy.
J Med Chem. 2001 Aug 2;44(16):2536-43. doi: 10.1021/jm0108404.
We have synthesized and evaluated a series of hybrids, denoted 22--27, for in vitro cytotoxic activity against a variety of cancer cell lines. These hybrids represent a molecular combination of polypyrrole minor groove binders structurally related to the natural antitumor agent distamycin A and two pyrazole analogues of the left-hand segment called cyclopropylpyrroloindole (CPI) of the potent antitumor antibiotic (+)-CC-1065. These novel water-soluble hybrids have been designed to enhance the minor groove binding ability of alkylating units 20 and 21, which should increase their clinical appeal by overcoming the administration problems of (+)-CC-1065 derivatives. The DNA alkylating and cytotoxic activities against several tumor cell lines are reported and discussed in terms of their structural differences in relation to both the number of N-methyl pyrrole rings and the type of the alkylating unit tethered to the oligopeptidic frame. It may be noted that, in general, and especially for 22--24, the cytotoxicity of the hybrids was much greater than that of the alkylating units alone. In only one case, compound 27, did the hybrid have cytotoxic activity comparable to that of the alkylating unit alone against FM3A/0 cells. The broadest spectrum of activity and greatest potency was shown by the hybrid 24, in which the alkylating unit 20 and the deformyl distamycin A are tethered by 1-methyl 2,5-dicarbonyl pyrazole, with IC(50) values for the different tumor cell lines ranging from 7 to 71 nM. For compounds 22--24, the increase of the length of the pseudopeptidic moiety from one to three N-methylpyrrole residues led to an increased cytotoxicity. Among the hybrids tested for their inhibitory effects on the proliferation of murine L1210 leukemia cell line, compound 24 proved to be the most active (IC(50) = 7.4 nM), and in the sequencing gel experiments, it showed the strongest and most highly sequence-specific DNA alkylation activity. For compounds 22-24, the sequence specificity of DNA alkylation appears to be affected by the modification of the number of pyrrole rings, and the correlation between cytotoxicity and alkylation pattern suggests that 24 exerts its cytotoxicity through DNA sequence-specific alkylation of the third adenine located in the sequence 5'-ACAAAAATCG-3'. The two other hybrids 22 and 23 were slightly less active for tumor cell proliferation, with IC(50) values of 58 and 19 nM, respectively. With only one exception, none of the compounds was endowed with antiviral activity at subtoxic concentrations. Compound 24 inhibited the effect of vaccinia virus at a concentration that was significantly lower than its minimum cytotoxic concentration for the E(6)SM host cells. These compounds gave distinct patterns of alkylation in AT-rich sequences, indicating that minor structural changes produced marked alterations in sequence selectivity.
我们合成并评估了一系列编号为22 - 27的杂合物,用于检测其对多种癌细胞系的体外细胞毒性活性。这些杂合物是聚吡咯小沟结合剂与天然抗肿瘤药物偏端霉素A在结构上的分子组合,以及强效抗肿瘤抗生素(+)-CC - 1065左手片段称为环丙基吡咯并吲哚(CPI)的两种吡唑类似物。设计这些新型水溶性杂合物是为了增强烷基化单元20和21的小沟结合能力,通过克服(+)-CC - 1065衍生物的给药问题,应能增加它们的临床应用价值。报道并讨论了这些杂合物对几种肿瘤细胞系的DNA烷基化和细胞毒性活性,涉及它们在N - 甲基吡咯环数量和连接到寡肽骨架上的烷基化单元类型方面的结构差异。可以注意到,一般来说,特别是对于22 - 24,杂合物的细胞毒性远大于单独的烷基化单元。仅在一种情况下,即化合物27,该杂合物对FM3A/0细胞的细胞毒性活性与单独的烷基化单元相当。杂合物24表现出最广泛的活性谱和最大的效力,其中烷基化单元20和去甲酰基偏端霉素A通过1 - 甲基 - 2,5 - 二羰基吡唑连接,不同肿瘤细胞系的IC(50)值范围为7至71 nM。对于化合物22 - 24,假肽部分长度从一个N - 甲基吡咯残基增加到三个导致细胞毒性增加。在测试其对小鼠L1210白血病细胞系增殖抑制作用的杂合物中,化合物24被证明是最具活性的(IC(50) = 7.4 nM),并且在测序凝胶实验中,它显示出最强和最高序列特异性的DNA烷基化活性。对于化合物22 - 24,DNA烷基化的序列特异性似乎受吡咯环数量修饰的影响,细胞毒性与烷基化模式之间的相关性表明,24通过对位于序列5'-ACAAAAATCG-3'中的第三个腺嘌呤进行DNA序列特异性烷基化发挥其细胞毒性。另外两种杂合物22和23对肿瘤细胞增殖的活性略低,IC(50)值分别为58和19 nM。除了一个例外,在亚毒性浓度下没有一种化合物具有抗病毒活性。化合物24在浓度显著低于其对E(6)SM宿主细胞的最小细胞毒性浓度时抑制痘苗病毒的作用。这些化合物在富含AT的序列中产生不同的烷基化模式,表明微小的结构变化会导致序列选择性发生显著改变。